StockpollyBeta
Get App
Popularity #2,296
ABUS · NASDAQ · Biotechnology

Arbutus Biopharma (ABUS)

Develops chronic HBV therapies while monetizing legacy lipid-nanoparticle IP.

$5.00
vs last close0.00 (0.00%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue522212211111791
Cost of revenue0180009900000
Gross profit5−15221−7−711111791
265212323727999107
Research & development20181516149956543
655858633464
Selling & marketing000000000000
General & administrative655858633464
Other expenses0−17004−111300000
Operating income−22−21−19−22−21−14−351−8−8169−6
1112211011411
Interest income112221111111
Interest expense000000000000
Other non-operating income−20−2−2−22−10−1−1−4−1−1
Income before tax−20−19−18−20−20−13−253−8−4170−5
Net income from continuing operations−20−19−18−20−20−13−253−8−4170−5
Net income−20−19−18−20−20−13−253−8−4170−5
EPS, basic−$0.12−$0.11−$0.10−$0.11−$0.10−$0.07−$0.13$0.01−$0.04−$0.02$0.88−$0.03
EPS, diluted−$0.12−$0.11−$0.10−$0.11−$0.10−$0.07−$0.13$0.01−$0.04−$0.02$0.87−$0.03
Weighted average shares, basic168168176188189186191192192192194197
Weighted average shares, diluted168168176188189190191192192192195197
EBITDA−20−20−17−19−19−15−243−8−4170−5
Depreciation & amortization000000000000
EBIT−20−21−18−20−20−16−243−8−4170−5